

Title: A cautionary tale of pyridoxine toxicity in cystathionine beta-synthase deficiency detected by two-tier newborn screening highlights the need for clear pyridoxine dosing guidelines

Running title: B6 toxicity in CBSD pyridoxine challenge

Authors: Ames EG^{a*}; Scott AJ^{a*}; Pappas KB^b; Moloney, S.M.^c; Conway RL^b; Ahmad A^a.

* Authors contributed equally

^a Division of Pediatric Genetics, Metabolism, and Genomic Medicine, Department of Pediatrics, University of Michigan Health System, Ann Arbor, Michigan

^b Division of Genetic, Genomic, and Metabolic Disorders, Children's Hospital of Michigan, Detroit, Michigan

^c Metabolic Newborn Screening Laboratory, Bureau of Laboratories, Michigan Department of Health and Human Services, Lansing, Michigan

Corresponding author: Elizabeth G. Ames, Division of Genetics, Metabolism, and Genomic Medicine, Department of Pediatrics, University of Michigan Health System, D5240 Medical Professional Building, 1500 E. Medical Center Dr, Ann Arbor, MI 48109; telephone: 734-763-0579; fax: 734-763-6561, email: amese@med.umich.edu

Funding: None

Keywords: Homocystinuria, pyridoxine responsive, hypermethioninemia

Data sharing statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of interest: The authors declare no conflict of interest.

Author Contributions: Conceptualization: E.A., A.S., R.C., and A.A.; patient care: E.A., A.S., K.P., and A.A.; data analysis: E.A., S.M., and R.C.; writing—original draft preparation: E.A. and

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/ajmg.a.61815](https://doi.org/10.1002/ajmg.a.61815)

A.S.; writing—review and editing: K.P., S.M., R.C., and A.A.; supervision: R.C. and A.A. All authors have read and agreed to the accepted version of the manuscript.

Abstract

Classic homocystinuria is due to deficiency of cystathionine beta-synthase (CBS), a pyridoxine-dependent enzyme that, depending on the molecular variants, may be co-factor responsive. Elevated methionine is often used as the primary analyte to detect CBS deficiency (CBSD) on newborn screening (NBS), but is limited by increased detection of other biochemical disorders with less clear clinical significance such as methionine aminotransferase (MAT) I/III heterozygotes. Our state has implemented a two-tier newborn screening (NBS) algorithm for CBSD that successfully reduced the number of MATI/III heterozygotes, yet effectively detected a mild, co-factor responsive form of CBSD. After initial diagnosis, newborns with CBSD often undergo a pyridoxine challenge with high-dose pyridoxine to determine responsiveness. Here we describe our NBS-identified patient with a mild form of pyridoxine responsive CBSD who developed respiratory failure and rhabdomyolysis consistent with pyridoxine toxicity during a pyridoxine challenge. This case highlights the need for weight-based dosing and duration recommendations for pyridoxine challenge in neonates.

Main text:

The state of Michigan began screening for homocystinuria and related disorders in 2004 using an elevated methionine as the primary analyte. The methionine:phenylalanine ratio

(Met/Phe) is also included in the first-tier screening algorithm as it allows for comparison of multiple amino acids that may be elevated nonspecifically due to transient dietary differences, use of total parenteral nutrition, or general liver health [Okun et al., 2017; Morris et al., 2017]. In 2015, Michigan implemented a second tier assay to improve specificity of methionine and Met/Phe as primary analytes (allowing NBS to keep CBSD false positives to a minimum) given that elevated methionine is seen in a number of conditions including MATI/III heterozygotes without clear clinical significance [Huemer et al., 2015; Keller et al., 2019; Sen et al., 2019]. Currently for samples from term newborns not admitted to the neonatal intensive care unit with a methionine ≥ 45 $\mu\text{mol/L}$ and a Met/Phe ≥ 1.0 , the initial NBS dried blood spot is sent to a reference lab (Mayo Medical Laboratories, Rochester, MN) to perform second-tier analysis of total homocysteine. If the total homocysteine level is greater than 15 $\mu\text{mol/L}$, the sample is considered a presumptive positive and prompts a referral to a metabolic follow-up clinic. To allow for timely management of more severe cases of CBSD, NBS samples with methionine ≥ 80 $\mu\text{mol/L}$ and Met/Phe ≥ 1.0 are considered presumptive positives and directly referred to a metabolic clinic for diagnostic testing.

Between 2004 and 2014, prior to the initiation of second-tier analysis of total homocysteine, there were 64 presumptive positive newborn screens prompting referral to a metabolic center. Confirmatory testing identified 3 confirmed cases of CBSD (none were pyridoxine responsive) and 12 cases of persistent isolated hypermethioninemia, all due to severe or partial MATI/III deficiency. There was one case of a mother with autosomal recessive

MAT1A deficiency whose methionine ranged from 800-1400 $\mu\text{mol/L}$ whose child's methionine levels normalized with confirmatory testing (Table 1). The remaining cases were all false positives. The positive predictive value of detecting CBSD with elevated methionine over this time was 4.7% (3 true positives / 64 total positive screens). Since initiation of two-tier screening, there were 7 presumptive positive referrals based on methionine elevation and elevated Met/Phe. None of these were confirmed to have CBSD. In addition, 57 samples were sent for second-tier testing. Of those 57 samples, only 3 were found to have elevated homocysteine levels. Upon confirmatory testing, two cases were found to be unaffected and the third case, as described below, was found to have pyridoxine-responsive CBSD (Table 1). The positive predictive value of detecting CBSD with second-tier screening with homocysteine was 10% (1 true positive / 10 total positive screens).

Our patient was identified by NBS to have an elevated methionine (73 $\mu\text{mol/L}$, normal < 45) and elevated Met/Phe ratio (1.6, normal < 1.0). Second-tier testing was notable for an elevated homocysteine (21.9 nmol/mL , normal < 15). Confirmatory plasma amino acids were obtained on day of life 8 that were notable for a mildly elevated methionine (54 $\mu\text{mol/L}$, normal 23-43) and elevated homocysteine (40 $\mu\text{mol/L}$, normal 5-15). Vitamin B12 (592 pg/mL) and folate (> 22.3 ng/mL) levels were both normal. Molecular testing for hypermethioninemia including the *CBS*, *GNMT*, *MAT1A*, and *ACHY* genes was sent. Additional metabolites of the methionine pathway (S-adenosylmethionine and S-adenosylhomocysteine) were unable to be sent due to insufficient blood volume.

Following these confirmatory labs, the patient was diagnosed with presumptive CBSD and started on pyridoxine at a dose of 100 mg daily (31 mg/kg/day) as a trial to determine pyridoxine responsiveness without introduction of medical formula. Homocysteine measured 7 days after pyridoxine initiation was again stably elevated (44 $\mu\text{mol/L}$). With no significant reduction in homocysteine level, pyridoxine dosing was increased to 200 mg daily (54 mg/kg/day) with a plan to recheck levels in one week. Roughly one week after dose increase (approximately two weeks of pyridoxine therapy), the patient suddenly developed dyspnea and cyanosis, followed by apnea, causing the caregiver to perform CPR. The patient was then transported via EMS to the Emergency Department (ED) for further evaluation.

On arrival to the ED, the patient initially appeared comfortable with even and unlabored respirations, but was noted to have intermittent peripheral arterial desaturations by pulse oximetry to SpO₂ 88-89% with exam. The patient continued to have intermittent apneic episodes lasting 30-40 seconds that progressed to more significant desaturations (SpO₂ 70-79%) with subsequent bradycardia of 60-69 beats per minute. Given the increased frequency of apneic episodes and bradycardia, she was intubated. The patient was then transferred to the pediatric intensive care unit for further management and close monitoring of her respiratory failure. Labs on admission were notable for elevated transaminases (AST 422, ALT 137 IU/L), elevated creatine kinase (CK) (5,973 IU/L, normal 26-180), homocysteine of 37 $\mu\text{mol/L}$, and methionine of 131 $\mu\text{mol/L}$. A broad spectrum of testing for other causes of apnea in a newborn was negative, including a full sepsis evaluation with CSF studies, viral respiratory PCR panel, brain MRI, and

long-term video EEG. Pediatric Genetics was consulted for further management of homocystinuria.

Based on her clinical presentation of apnea leading to respiratory failure, elevated transaminases, and elevated CK, pyridoxine toxicity was strongly suspected and genetics recommended cessation of pyridoxine until improvement of her clinical picture and molecular confirmation of her diagnosis. Within 72 hours of pyridoxine cessation, the patient's respiratory drive had improved and she was extubated to non-invasive positive pressure ventilation for several days before being weaned to supplemental oxygen via nasal cannula. While she was critically ill, enteral feeding was held and nutrition was provided via dextrose-containing fluids and intravenous lipids.

During her admission, the results of molecular testing returned and revealed two pathogenic variants in the *CBS* gene: c.833T>C, p.Ile278Thr and c.476_477insCAGGCC, p.Val160Argfs*4, the latter of which has not been previously described. The former is a pathogenic variant that is associated with pyridoxine-responsive CBSD. Prior to discharge and 7 days after admission, her elevations in CK, AST, and ALT continued to downtrend and pyridoxine was reinitiated at 10 mg/kg dose prior to discharge. Although she clearly did not respond clinically in a classic pyridoxine-responsive manner, genotype-phenotype correlation of CBS compound heterozygotes is difficult to predict [Morris et al., 2017] and a safe dose of pyridoxine was continued to provide potential benefit in the event that she was partially responsive to pyridoxine.

Labs performed one week after hospital discharge on a breast milk-based diet were notable for a normal CK, normal AST/ALT, a homocysteine of 56 $\mu\text{mol/L}$, and methionine of 268 $\mu\text{mol/L}$. Due to maternal concerns about pyridoxine toxicity, patient's pyridoxine dose was less than what we recommended (ultimately around 7-8 mg/kg/day instead of recommended 10-20 mg/kg/day). Repeat labs one week later revealed a homocysteine of 59 $\mu\text{mol/L}$ and methionine of 589 $\mu\text{mol/L}$, but these were noted to be post-prandial samples. Preprandial labs repeated one week later were again notable for persistent elevations in methionine (641 $\mu\text{mol/L}$) and homocysteine (66 $\mu\text{mol/L}$). A partial methionine-restricted diet was initiated (total methionine intake of 25-30 mg/kg/day) and subsequent labs were notable for a methionine of 77 $\mu\text{mol/L}$ and a homocysteine of 39 $\mu\text{mol/L}$. At 6 months of age, she has continued on pyridoxine 10 mg/kg/day and a partial methionine-restricted diet. She has attained age-appropriate milestones and has normal growth parameters. Her methionine levels are below 100 $\mu\text{mol/L}$ and her homocysteine levels are below 50 $\mu\text{mol/L}$.

Discussion

Classic homocystinuria or CBS is the most common inborn error of sulfur metabolism due to pathogenic variants in the *CBS* gene [Kruger, 2017]. There is a wide range of presentations based on the severity of the disease and include developmental delay, ectopia lentis, Marfanoid habitus, osteoporosis, intellectual disability, thromboembolic events, and even some reports of asymptomatic adults. [Gibson et al., 1964; Poloni et al., 2018]. From a biochemical perspective, there is also a wide range of phenotypes including mild homocysteine

elevations that are highly responsive to pyridoxine compared to pyridoxine-unresponsive forms that require extensive methionine restriction and medical management with betaine. One of the most common pathogenic variants in the *CBS* gene is c.833T>C (p.Ile278Thr) which accounts for approximately 25% of all pathogenic variants identified and is pan-ethnic [Moat et al., 2004]. The p.Ile278Thr variant is associated with at least some degree of pyridoxine responsiveness [Morris et al., 2017] and results in a less severe disease phenotype [Shih et al., 1995; Kluijtmans et al., 1999]. Epidemiologic studies suggest that the expected incidence of individuals with CBSD -- especially when taking into account the frequency of the p.Ile278Thr allele -- should be much more than the frequency of those actually identified by standard NBS methods [Gustadnes et al., 1999]. Similarly, one study suggested that NBS will only identify 25% of CBSD cases when hypermethioninemia is used as the primary analyte [Sokolová et al., 2001]. The recently published guidelines for CBSD emphasize this point. The sensitivity of CBSD detection by NBS with hypermethioninemia alone is probably very low unless paired with a two-tier system [Huemer et al., 2015; Morris et al., 2017; Keller et al., 2019] as our state has implemented. To our best estimate, the incidence of CBSD in Michigan for October 2004 through January 2015 is 1:400,000 (calculated on total number of NBS performed each year with the exception of 2005 where data is not available, a stable birth rate compared to 2006 was assumed). The incidence of CBSD in Michigan between February 2015 to December 2019 is estimated to be 1:500,000 (calculated on total number of NBS performed with the exception of 2019 where data has not been reported yet and the birth rate was assumed to be stable compared

to 2018). In comparison, our estimation of CBSD incidence based on clinically ascertainment prior to NBS is roughly 1 in 1,000,000 (assuming Michigan has roughly 100,000 births per year and we have on average one CBSD patient per decade who predate NBS). Our state's data supports that the two-tier screening system improves the positive predictive value of NBS while overall detecting a similar number of patients. The primary benefit of such a two-tier system, when methionine is the primary analyte for detection, is that this approach allows for lower methionine cutoffs to detect mild forms of CBSD while resulting in a relatively low number of referrals by improving specificity with a second tier screening of total homocysteine level as has been reported elsewhere [Turgeon et al., 2010; Mudd, 2011; Alodaib et al., 2012; Keller et al., 2019]. In our state, we have shown that many of the elevations of methionine found through NBS were ultimately due to confirmed or presumed mutations in *MAT1A*, the gene responsible for MAT I/III deficiency [Sen et al., 2019]. However, utilizing a two-tier approach allowed NBS to successfully discriminate a true and mild case of CBSD.

Adverse effects to pyridoxine have been previously reported in other neonates with apnea after receiving high doses of pyridoxine [Mudd et al., 2001]. Our patient's presentation was similar to a Japanese infant with CBSD who received 100 mg/kg for 8 days before she developed apneic respiratory failure, rhabdomyolysis, and elevated transaminases; the infant recovered fully over a few weeks after pyridoxine cessation [Shoji et al., 1998]. There are several differences between this case and our patient. Our patient was only prescribed 200 mg daily (54 mg/kg/day) for 7 days following a 7-day period of receiving 100 mg daily (31 mg/kg/day). The neonate

described in Shoji et al. also had markedly elevated methionine levels (1340-1630 $\mu\text{mol/L}$) whereas our patient had less significant hypermethionemia (methionine $< 1000 \mu\text{mol/L}$). Our case suggests a lower dose can cause pyridoxine toxicity in early infancy. In the guidelines for CBSD management, a pyridoxine challenge of 10 mg/kg/day is recommended for at least 7 days. However, there is a special exception for neonates detected by NBS who are presumed to be more severe and less likely to respond to pyridoxine and should receive a relatively high dose of pyridoxine (100 mg/day) for 2 weeks [Morris et al., 2017]. These guidelines also report a range of doses for pyridoxine challenge of 100-500 mg/day for 1-2 weeks, which for a 3-4 kg neonate is a minimum dose of 25-33 mg/kg/day to a maximum dose of 125-167 mg/kg/day. The management guidelines proposed in GeneReviews recommends a pyridoxine challenge of a shorter duration to find the lowest possible dose to produce the maximum biochemical benefit (defined as 30% or more reduction in homocysteine). For neonates detected by NBS this would entail 100 mg/day for 2 days (25-33 mg/kg/day assuming 3-4 kg neonate), checking methionine and homocysteine levels, and 2 additional dose escalations over the next 4 days to 200 mg/day (50-66 mg/kg/day) and 300 mg/day (75-100 mg/kg/day) to determine pyridoxine responsiveness [Sacharow et al., 2004]. Commonly used biochemical textbooks vary in their recommendations for pyridoxine challenge including 100 mg daily for two weeks [Saudubray et al., 2016] to a dose escalation from 100 mg daily (25-33 mg/kg/day) to 500 mg daily (125-167 mg/kg/day) over multiple weeks [Blau et al., 2014].

Our case highlights the importance and risks associated with pyridoxine challenge in neonates with CBSD. The current clinical practice guidelines and literature for pyridoxine challenges doesn't clearly discriminate recommended doses based on age, weight, and suspicion of clinical pyridoxine responsiveness (as indicated by homocysteine level). The recommendations for dose escalation in a pyridoxine challenge may not be appropriate for all infants. It is also possible that additional factors, as yet undetermined, may predispose some neonates to toxic effects of pyridoxine at doses which are well tolerated by other neonates. Until the risks of pyridoxine toxicity are better understood, current recommendations could be strengthened by clear weight-based dosing and duration for pyridoxine therapy, especially for neonates detected by newborn screening when assessing for co-factor responsiveness. As molecular testing confirmation becomes more widely available, the knowledge of specific pathogenic variants may also be a crucial determinant in the pyridoxine responsiveness and the pyridoxine dose escalation chosen by providers. We propose that for neonates with CBSD detected by NBS that a pyridoxine challenge would be completed over a relatively short period of time and with a careful review with parents of the adverse side effects associated with pyridoxine toxicity including risk of apnea. Given that our patient had clinically significant apnea at 50 mg/kg/day, we would recommend starting at 10 mg/kg/day for 4 days, increasing to 20 mg/kg/day for 4 days if no appreciable change in homocysteine level, and using 40 mg/kg/day as a maximum dose for another 4 days. We recommend extreme caution in neonates for doses approaching or in excess of 200 mg daily and to use weight-based doses when possible.

Pyridoxine is also used for patients with pyridoxine dependent epilepsy with a recommended maximum dose of 40 mg/kg/day for short periods of time during illnesses [van Karnebeek et al., 2015]. While this disorder has a completely different mechanism, it is another helpful measure of what is generally considered safe by weight-based standards. We acknowledge that future case reports or therapeutic studies may alter our recommendations. We encourage providers to proceed with caution when selecting doses for performing neonatal pyridoxine challenges for NBS-detected patients with CBSD and follow neonates closely for pyridoxine toxicity or side effects.

Acknowledgments:

The authors thank the Newborn Screening Program personnel at the Michigan Department of Health and Human Services for their collaborative assistance.

References

- Alodaib AN, Carpenter K, Wiley V, Wotton T, Christodoulou J, Wilcken B. 2012. Homocysteine measurement in dried blood spot for neonatal detection of homocystinurias. In: JIMD Rep. Springer, p 1–6.
- Blau N, Duran M, Gibson KM, Dionisi-Vici C eds. 2014. Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. Springer Berlin Heidelberg.
- Gaustadnes M, Ingerslev J, Rutiger N. 1999. Prevalence of congenital homocystinuria in Denmark. *New Engl J Med* 340: 1513.
- Gibson JB, Carson NA, Neill DW. 1964. Pathological Findings in Homocystinuria. *J Clin Pathol*

17: 427–437.

Huemer M, Kožich V, Rinaldo P, Baumgartner MR, Merinero B, Pasquini E, Ribes A, Blom HJ.

2015. Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines. *J Inherit Metab Dis* 38: 1007–1019.

van Karnebeek CDM, Stockler-Ipsiroglu S, Jaggumantri S, Assmann B, Baxter P, Buhas D, Bok LA, Cheng B, Coughlin CR, Das AM, Giezen A, Al-Hertani W, Ho G, Meyer U, Mills P, Plecko B, Struys E, Ueda K, Albersen M, Verhoeven N, Gospe SM, Gallagher RC, Van Hove JKL, Hartmann H. 2015. Lysine-restricted diet as adjunct therapy for pyridoxine-dependent epilepsy: The PDE consortium consensus recommendations. In: *JIMD Rep*. Springer, p 47–57.

Keller R, Chrastina P, Pavlíková M, Gouveia S, Ribes A, Kölker S, Blom HJ, Baumgartner MR, Bártil J, Dionisi-Vici C, Gleich F, Morris AA, Kožich V, Huemer M, Barić I, Ben-Omran T, Blasco-Alonso J, Bueno Delgado MA, Carducci C, Cassanello M, Cerone R, Couce ML, Crushell E, Delgado Pecellin C, Dulin E, Espada M, Ferino G, Fingerhut R, Garcia Jimenez I, Gonzalez Gallego I, González-Irazabal Y, Gramer G, Juan Fita MJ, Karg E, Klein J, Konstantopoulou V, la Marca G, Leão Teles E, Leuzzi V, Lilliu F, Lopez RM, Lund AM, Mayne P, Meavilla S, Moat SJ, Okun JG, Pasquini E, Pedron-Giner CC, Racz GZ, Ruiz Gomez MA, Vilarinho L, Yahyaoui R, Zerjav Tansek M, Zetterström RH, Zeyda M. 2019. Newborn screening for homocystinurias: Recent recommendations versus current practice. *J Inherit Metab Dis* 42: 128–139.

- Kluijtmans LAJ, Boers GHJ, Kraus JP, Van Den Heuvel LPWJ, Cruysberg JRM, Trijbels FJM, Blom HJ. 1999. The molecular basis of cystathionine β -synthase deficiency in Dutch patients with homocystinuria: Effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. *Am J Hum Genet* 65: 59–67.
- Kruger WD. 2017. Cystathionine β -synthase deficiency: Of mice and men. *Mol Genet Metab* 121: 199–205.
- Moat SJ, Bao L, Fowler B, Bonham JR, Walter JH, Kraus JP. 2004. The molecular basis of cystathionine β -synthase (CBS) deficiency in UK and US patients with homocystinuria. *Hum Mutat* 23: 206–206.
- Morris AAM, Kožich V, Santra S, Andria G, Ben-Omran TIM, Chakrapani AB, Crushell E, Henderson MJ, Hochuli M, Huemer M, Janssen MCH, Maillot F, Mayne PD, McNulty J, Morrison TM, Ogier H, O’Sullivan S, Pavlíková M, de Almeida IT, Terry A, Yap S, Blom HJ, Chapman KA. 2017. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. *J Inherit Metab Dis* 40: 49–74.
- Mudd S, Levy H, Kraus J. 2001. Disorders of transulfuration. In: Scriver C, Beaudet A, Sly W, Valle D, editors. *The Metabolic and Molecular Bases of Inherited Disease*. McGraw Hill, p 2016–40.
- Mudd SH. 2011. Hypermethioninemias of genetic and non-genetic origin: A review. *Am J Med Genet C Semin Med Genet* 157: 3–32.
- Okun JG, Gan-Schreier H, Ben-Omran T, Schmidt K V., Fang-Hoffmann J, Gramer G, Abdoh

G, Shahbeck N, Al Rifai H, Al Khal AL, Haege G, Chiang CC, Kasper DC, Wilcken B, Burgard P, Hoffmann GF. 2017. Newborn screening for Vitamin B6 non-responsive classical homocystinuria: Systematical evaluation of a two-tier strategy. In: *JIMD Reports*. Springer, p 87–94.

Poloni S, Sperb-Ludwig F, Borsatto T, Weber Hoss G, Doriqui MJR, Embiruçu EK, Boa-Sorte N, Marques C, Kim CA, Fischinger Moura de Souza C, Rocha H, Ribeiro M, Steiner CE, Moreno CA, Bernardi P, Valadares E, Artigalás O, Carvalho G, Wanderley HYC, Kugele J, Walter M, Gallego-Villar L, Blom HJ, Schwartz IVD. 2018. CBS mutations are good predictors for B6-responsiveness: A study based on the analysis of 35 Brazilian Classical Homocystinuria patients. *Mol Genet Metab* 6: 160–170.

Sacharow S, Picker J, Levy H. 2004. Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. In: Adam M, Ardinger H, Pagon R, Al. E, editors. *GeneReviews*.

Saudubray JM, Baumgartner MR, Walter JH eds. 2016. *Inborn Metabolic Diseases: Diagnosis and Treatment*, 6th ed. Springer Berlin Heidelberg.

Sen K, Felice M, Bannick A, Colombo R, Conway R. 2019. Mild Persistent Isolated Hypermethioninemia Identified through Newborn Screening in Michigan. *J Pediatr Genet* 08: 054–057.

Shih VE, Fringer JM, Mandell R, Kraus JP, Berry GT, Heidenreich RA, Korson MS, Levy HL, Ramesh V. 1995. A Missense Mutation (I278T) in the Cystathionine Beta-Synthase Gene Prevalent in Pyridoxine-Responsive Homocystinuria and Associated With Mild Clinical

Phenotype - PubMed. *Am J Hum Genet* 57: 34–39.

Shoji Y, Takahashi T, Sato W, Shoji Y, Takada G. 1998. Acute life-threatening event with rhabdomyolysis after starting on high-dose pyridoxine therapy in an infant with homocystinuria. *J Inherit Metab Dis* 21: 439–440.

Sokolová J, Janošíková B, Terwilliger JD, Freiburger T, Kraus JP, Kozich V. 2001. Cystathionine beta-synthase deficiency in Central Europe: Discrepancy between biochemical and molecular genetic screening for homocystinuric alleles. *Hum Mutat* 18: 548–549.

Turgeon CT, Magera MJ, Cuthbert CD, Loken PR, Gavrilov DK, Tortorelli S, Raymond KM, Oglesbee D, Rinaldo P, Matern D. 2010. Determination of total homocysteine, methylmalonic acid, and 2-methylcitric acid in dried blood spots by tandem mass spectrometry. *Clin Chem* 56: 1686–1695.

Table 1.

Year	Hcy 2nd tier	+ 2nd tier	Pres +	T+ CBSD	Hyper Met	Mat <i>MATIA</i>	Changes to methionine cutoff and/or platform
2004 (October)			6	0	0	0	Met = 87 $\mu\text{mol/L}$, M/P ≥ 1.3
2005			10	0	0	0	
2006			7	0	0	0	
2007			1	0	0	0	Met = 74 $\mu\text{mol/L}$, M/P ≥ 1.3
2008			1	0	1	0	
2009			2	1	1	0	
2010			6	0	3	0	
2011			7	0	3	0	Met = 56 (switch from NeoGram to NeoBase)
2012			11	2	2	1	
2013			5	0	1	0	
2014			8	0	1	0	
2015 (January)	7	2	2	0	0	0	
2016	6	0	2	0	0	0	
2017	18	0	2	0	1	0	
2018	11	0	1	0	0	0	
2019	15	1	0	1	0	0	Met = 45 (switch from NeoBase to NeoBase2)

	Hcy 2nd tier	+ 2nd tier	Pres +	T+ CBSD	Hyper Met	Mat <i>MATIA</i>
Pre-2nd tier			64	3	12	1
Post-2nd tier	57	3	7	1	1	0

Hcy = homocysteine, Pres + = presumptive positive, T+ CBSD = true positive CBS deficiency, Hyper Met = persistent isolated hypermethioninemia, Mat *MATIA* = maternal autosomal recessive *MATIA* deficiency

NAME: ELLIE ZHAOMRN (REG #): 101168077BIRTHDATE: 10/19/2019

Request and Consent to Photography and/or Video Record

Your provider may need to photograph and/or record you to document a medical condition, help with the diagnosis and/or treatment of a condition, and/or to help plan details of surgery. Photographs and/or recordings taken for these clinical reasons do not require your written permission. Your provider does need your written permission to use your photographs and/or video recordings for the non-clinical reasons below.

I hereby authorize the (Name of service, clinic, or department) Pediatric Genetics, including the attending doctor or other designated person(s), to photograph and/or video record me for the following purposes: Check YES or NO.

- | | YES | NO |
|---|-------------------------------------|--------------------------|
| 1. For the advancement of not-for-profit medical purposes, including teaching, research and education. I understand that education is an important part of the hospital's commitment to teaching younger healthcare providers. | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| 2. To show or release to current or future UMHS patients for the purpose of education and consultation. I understand these photos or videos can be taken at any time during my treatment which includes pre-treatment, post-treatment, pre-operative, intra-operative, post-operative photos, and/or videos of my treatment, surgery and/or procedure | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| 3. For external not-for-profit educational purposes outside UMHS such as lectures and presentations at professional conferences. | <input checked="" type="checkbox"/> | <input type="checkbox"/> |

I consent to photographs and/or video recordings under the following conditions:

- Copies of the photos, videos, and/or films may be released to me if I ask for them.
- I can refuse to have photos and/or video taken without any change in my medical care at UMHHC.
- I understand and agree that although my name will not be used, it may be possible to identify me from a photo and/or video and
- I understand that once released outside UMHS, UMHS does not have control over the photos or videos.

Revoking Permission: This authorization has no expiration date; but I may revoke it at any time by writing to the Health Information Management Department at the address below. I must state in writing that I no longer give consent for photo(s) and/or video(s) or for the use of any photo(s) or video(s) that were already taken.

I have had enough time to discuss with my provider the information on this form. I have had the chance to ask questions and my questions have been answered. I have read and understand the information. I hereby release the hospital, its personnel, and any other persons participating in my care from any and all liability which may or could arise from the taking or authorized use of such photographs and/or video recordings.

X Xin Song
Signature of Patient or Legally Authorized Representative (if patient is a minor or unable to sign)

12/09/2019
Date (mm/dd/yyyy)

Xin Song
Printed Name of Legally Authorized Representative (if patient is a minor or unable to sign)
Relationship Spouse Parent Next of Kin Legal Guardian DPOA for Healthcare

William Wang MDI PhD
Consent Obtained, Explained and Witnessed By

12/09/2019 1645 A.M./P.M.
Date (mm/dd/yyyy) Time

University of Michigan Health System Health Information Management
Release of Information Unit 2901 Hubbard Rd #2722 Ann Arbor, Michigan 48109-2435
Phone: (734) 936-5490 Fax: (734) 936-8571

TO PROVIDERS: Photographs and/or recordings taken for a clinical purpose do not require written consent. The photographs or video recording will be made part of the medical record. Written consent must be obtained prior to taking and/or using a photograph and/or recording for non-clinical purposes. If a photograph or recording is initially taken for a clinical purpose, and later deemed appropriate for a non-clinical purpose, written consent must be obtained prior to using the photograph or recording for the non-clinical purpose. For photography and/or video recording of patients related to research, please refer to the IRB website. For photography and/or video recording of patients for use in promotional or marketing materials, please use a form link: [Permission to Release Information Including Photographs, Videos, Electronic or Other Media](#)

Page 1 of 1

31-10047

VER: A/11
HIM: 12/11Original - Medical Record
Copy - Patient / FamilyRequest and Consent to
Photography and/or Video Record